Department of Pharmaceutical Pathophysiology, Medical University of Gdansk, Debinki 1, 80-211 Gdansk, Poland.
Curr Med Chem. 2021;28(27):5527-5550. doi: 10.2174/0929867328666201231121704.
Cancer, along with cardiovascular diseases, is globally defined as the leading cause of death. Importantly, some risk factors are common to these diseases. The process of angiogenesis and platelet aggregation is observed in cancer development and progression. In recent years, studies have been conducted on nanodrugs for these diseases that have provided important information on the biological and physicochemical properties of nanoparticles. Their attractive features are that they are made of biocompatible, well-characterized, and easily functionalized materials. Unlike conventional drug delivery, sustained and controlled drug release can be obtained by using nanomaterials.
In this article, we review the latest research to provide comprehensive information on nanoparticle-based drugs for the treatment of cancer, cardiovascular disease associated with abnormal haemostasis, and the inhibition of tumor-associated angiogenesis.
The results of the analysis of data based on drugs with nanoparticles confirm their improved pharmaceutical and biological properties, which give promising antiplatelet, anticoagulant, and antiangiogenic effects. Moreover, the review included in vitro, in vivo research and presented nanodrugs with chemotherapeutics approved by Food and Drug Administration.
By the optimization of nanoparticle size and surface properties, nanotechnology is able to deliver drugs with enhanced bioavailability in treatment of cardiovascular disease, cancer and inhibition of cancer-related angiogenesis. Thus, nanotechnology can improve the therapeutic efficacy of the drug, but there is a need for a better understanding of the nanodrugs interaction in the human body because this is a key factor in the success of potential nanotherapeutics.
癌症与心血管疾病一起，在全球范围内被定义为主要死因。重要的是，一些风险因素与这些疾病共同存在。血管生成和血小板聚集的过程在癌症的发展和进展中被观察到。近年来，针对这些疾病的纳米药物进行了研究，这些研究提供了有关纳米颗粒的生物学和物理化学性质的重要信息。它们的吸引人之处在于它们由生物相容性好、特征明确且易于功能化的材料制成。与传统药物递送不同，纳米材料可以实现持续和控制药物释放。
在本文中，我们回顾了最新的研究，提供了关于基于纳米颗粒的药物治疗癌症、与异常止血相关的心血管疾病和抑制肿瘤相关血管生成的全面信息。
基于具有纳米颗粒的药物的数据分析结果证实了它们改善的药物和生物学特性，这些特性赋予了有前途的抗血小板、抗凝和抗血管生成作用。此外，该综述包括了已批准的经食品和药物管理局批准的用于治疗癌症和心血管疾病的纳米药物的体外和体内研究。
通过优化纳米颗粒的大小和表面特性，纳米技术能够在治疗心血管疾病、癌症和抑制癌症相关血管生成方面提高药物的生物利用度。因此，纳米技术可以提高药物的治疗效果，但需要更好地了解纳米药物在人体中的相互作用，因为这是潜在纳米治疗成功的关键因素。
